Evidence map›Paper›PMID 35974872›Full record

ArticleInternational journal of nanomedicine2022

Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy.

Tingting Chen, Bingxiang Ma, Shi Lu, Lupeng Zeng, Huaying Wang, Wanhua Shi, Linying Zhou, Yaokun Xia, Xi Zhang, Jing Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Tingting Chen *School of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Bingxiang Ma *School of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Shi LuSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Lupeng ZengSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Huaying WangSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Wanhua ShiSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Linying ZhouElectron Microscopy Facility, Public Technology Service Center, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Yaokun XiaKey Laboratory of the Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Xi ZhangSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Jing ZhangDepartment of Chemical Biology, College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian Province, 350002, People's Republic of China.
Jinghua ChenSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, 350108, People's Republic of China.
Fujian Medical University · CNFujian Agriculture and Forestry University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: In recent years, a variety of nanoparticles with excellent anticancer and delivery properties have emerged for cancer therapy. However, potential toxicity, high production cost and complex preparation procedures have been obstacles to their use in biomedicine. Here, we obtained cucumber-derived nanovesicles (CDNVs) at high yield and low cost by simple juicing and ultracentrifugation. The anticancer effects of CDNVs were evaluated in vitro and in vivo. Methods: Transmission electron microscope, nanoparticle tracking analysis and laser particle size analysis were used to characterize the morphology, diameter and zeta potential of CDNVs, respectively. The anticancer effects of CDNVs in vitro were evaluated by MTT and apoptosis assays. The mechanism was further explored by measuring the protein levels of signal transducer and activator of transcription 3 pathway, reactive oxygen species, cell cycle distribution and caspase activity. In-vivo anticancer efficacy was evaluated by measuring tumor volume and weight of mice in three different treatment groups (CDNVs, cucurbitacin B and PBS). Results: CDNVs inhibited proliferation of human non-small cell lung cancer cells by suppressing signal transducer and activator of transcription 3 activation, generating reactive oxygen species, promoting cell cycle arrest, and activating the caspase pathway. These CDNVs exhibited strong anticancer effects both in vitro and in vivo, and reduced the rate of tumor growth without obvious toxicity to mouse visceral organs. Compared with an equivalent dose of cucurbitacin B, CDNVs exerted stronger anticancer effects in vitro and in vivo. Conclusion: These results demonstrate that CDNVs suppress tumor growth. This study addresses the development of cancer therapeutic drugs using plant-derived nanovesicles that are cost-efficient, simple to produce in high yields, and provide an alternative approach to drug isolation that may help advance sustainability of medicinal plants.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCucumis sativusLung NeoplasmsTriterpenesAnimalsApoptosisCaspasesCell Line, TumorCell ProliferationHumansMiceReactive Oxygen SpeciesSignal TransductionSTAT3 Transcription FactorAntineoplastic AgentsCaspasescucurbitacin BReactive Oxygen SpeciesSTAT3 Transcription FactorTriterpenesanticancercucurbitacin BROSSTAT3

Identifiers

PMID35974872
PMCPMC9376005
OpenAlexW4294265791

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.